Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands

Wall Street lifts obesity drug targets for Eli Lilly and AbbVie as a new Medicare GLP-1 Bridge program expands access to Zepbound and Lilly's oral pill Foundayo.

Biotech · Markets Commentary NYSE: LLY JPMorgan lifted Eli Lilly to $1,400 and AbbVie drew a string of target hikes as a new Medicare GLP-1 program widens acc...